Tricyclic compound and its pharmaceutical composition and application

By developing a novel structured triangular ring compound that binds SOS1 catalytic site to inhibit KRAS:SOS1 interaction, the problem of poor effectiveness of existing SOS1 inhibitors is solved, and effective inhibition of KRAS mutant cancer cells is achieved and Treatment of various cancers.

CN115677699BActive Publication Date: 2024-11-22WUHAN YUXIANG PHARM TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110838486.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-07-23
Publication Date
2024-11-22
Estimated Expiration
2041-07-23

AI Technical Summary

Technical Problem

Existing SOS1 inhibitors have limited effectiveness in inhibiting KRAS-SOS1 interactions and are difficult to significantly reduce ERK phosphorylation in KRAS mutant cancer cell lines, making them unable to effectively treat diseases caused by SOS1 overexpression.

Method used

A class of novel structured triangular ring compounds were developed to prevent the interaction and activation of RAS family proteins by binding to SOS1 catalytic sites, thereby significantly inhibiting KRAS:SOS1 activation and achieving nM-level inhibitory effect, suitable for treatment and SOS1 activation-related diseases such as pancreatic cancer, colorectal cancer and lung cancer.

Benefits of technology

The compound showed excellent cell proliferation inhibitory activity, with an IC50 value reaching nM level, and had a very good inhibitory effect on KRAS:SOS1 activation. It is suitable for the prevention and treatment of diseases caused by SOS1 overexpression, especially cancers related to KRAS mutations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115677699B_ABST
    Figure CN115677699B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of pharmaceutical chemistry, and relates to tricyclic compounds and pharmaceutical compositions and applications thereof. The compound is a tricyclic compound as shown in Formula I, or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, metabolite or prodrug thereof, and the R1 to R3 and L1, L2, X1, X2, X3, X4, X5, Y1, Y2 and A groups are as defined in the specification. The compound and the pharmaceutical composition comprising the compound of the present invention have good SOS1 inhibitory activity, and thus can be used as an SOS1 inhibitor, and used to prepare drugs for treating and / or preventing diseases such as cancer caused by overexpression of SOS1, and thus are widely used in the field of medicine. The tricyclic compound of the present invention exhibits excellent biological activity and drugability, and has great prospects for drug development. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical chemistry, and specifically relates to a class of tricyclic compounds, a pharmaceutical composition containing the compounds and applications thereof in the medical field. Background Art

[0002] Since the discovery of the RAS family GTPase (which includes members KRAS, NRAS, and HRAS) associated with cancer in late 1982, the incidence in human cancers has been as high as 20% to 30%. RAS proteins act as molecular switches that cycle between an active GTP-bound state and an inactive GDP-bound state. Activated by guanine nucleotide exchange factors (GEFs), RAS in its GTP-bound state interacts with many effectors. The return to the inactive state is driven by GTPase activating proteins (GAPs), which downregulate active RAS by accelerating the weak intrinsic GTPase activity by up to 5 orders of magnitude.

[0003] Whether mutant RAS proteins require GEF activity for full activation remains to be fully investigated and may vary depending on the specific mutation. The most studied RAS sevenless son (SOS) protein has two known human isoforms, SOS1 and SOS2. Attempts to inhibit the RAS-SOS interaction by peptide mimicking with nanomolar affinity orthosteric SOS helices identified hydrocarbon-stapled peptides but had only low cellular activity. Fragment-based screening, rational design, and high-throughput screening approaches have led to the identification of small molecules addressing the KRAS-SOS1 interaction with moderate micromolar affinities.

[0004] SOS1 protein consists of 1333 amino acids (150kDa). SOS1 is a multi-domain protein with two tandem N-terminal histone domains (HD), followed by a Dbl homology domain (DH), a Pleckstrin homology domain (PH), a helical linker (HL), a RAS exchange motif (REM), a CDC25 homology domain, and a C-terminal proline-rich domain (PR). SOS1 has two binding sites for RAS family proteins; a catalytic site that binds GDP-bound RAS family proteins to promote guanine nucleotide exchange; an allosteric site that binds GTP-bound RAS family proteins, which leads to a further increase in the catalytic GEF function of SOS1. Public data show that SOS1 is critically involved in mutant KRAS activation and oncogenic signaling in cancer (Jeng et al., Nat. Commun., 2012, 3: 1168). Depletion of SOS1 levels reduced the proliferation rate and survival of tumor cells carrying KRAS mutations, whereas no effect was observed in KRAS wild-type cell lines. The effects of SOS1 loss could not be rescued by the introduction of SOS1 with catalytic site mutations, demonstrating the important role of SOS1GEF activity in KRAS mutant cancer cells.

[0005] SOS1 is critically involved in the activation of RAS family protein signaling in cancer by mechanisms other than RAS family protein mutations. SOS1 interacts with the adaptor protein Grb2, and the resulting SOS1 / Grb2 complex binds to activated / phosphorylated receptor tyrosine kinases (e.g., EGFR, ErbB2, ErbB3, ErbB4, PDGFR-A / B, FGFR1 / 2 / 3, IGF1R, INSR, ALK, ROS, TrkA, TrkB, TrkC, RET, c-MET, VEGFR1 / 2 / 3, AXL) (Pierre et al., Biochem. Pharmacol., 2011, 82(9): 1049-56). SOS1 is also recruited to other phosphorylated cell surface receptors, such as T cell receptor (TCR), B cell receptor (BCR) and monocyte colony stimulating factor receptor (Salojin et al., J. Biol. Chem. 2000, 275 (8): 5966-75). This localization of SOS1 to the plasma membrane proximal to the RAS family protein enables SOS1 to promote RAS family protein activation. SOS1 activation of RAS family proteins can also be mediated by the interaction of SOS1 / Grb2 with the BCR-ABL oncoprotein common in chronic myeloid leukemia.

[0006] SOS1 is also a GEF for activating the GTPase RAC1 (Ras-related C3 botulinum toxin substrate 1) (Innocenti et al., J. Cell Biol., 2002, 156(1):125-36). Like RAS family proteins, RAC1 is involved in the pathogenesis of a variety of human cancers and other diseases (Bid et al., Mol. Cancer Ther. 2013, 12(10):1925-34).

[0007] Herein, we describe novel SOS1 inhibitor compounds that bind to the SOS1 catalytic site and simultaneously prevent interaction with RAS family proteins and their activation. This results in the inhibition of SOS1 binding to RAS family proteins, particularly KRAS (with low single-digit nanomolar IC 50 The results showed that the phosphorylation of ERK was significantly reduced in KRAS mutant cancer cell lines due to the significant inhibition of the interaction of ERK and ERK activity.

[0008] It is expected that the selective SOS1 inhibitor compounds described herein provide pharmacological benefits for patients suffering from cancers associated with dependence on RAS family protein signaling. Such cancers expected to be targeted by SOS1 inhibitor compounds include those showing changes (mutations, gene amplifications, overexpressions) of components (proteins, genes) in RAS family protein pathways, such as KRAS, NRAS, HRAS, receptor tyrosine kinases (e.g., EGFR, ErbB2, ErbB3, ErbB4, PDGFR-A / B, FGFR1 / 2 / 3, IGF1R, INSR, ALK, ROS, TrkA, TrkB, TrkC, RET, c-MET, VEGFR1 / 2 / 3, AXL), GAPs (e.g., NF1) and SOS1. In addition, in view of the role of SOS1 in RAC1 activation, cancers showing dependence on RAC1 are expected to be targeted by SOS1 inhibitor compounds. Furthermore, SOS1 inhibitor compounds are expected to provide pharmacological benefit in other diseases associated with dysregulation of RAS family protein pathways such as neurofibromatosis, Noonan syndrome (NS), cardiofacial-cutaneous syndrome (CFC), and hereditary gingival fibromatosis type 1. Summary of the invention

[0009] Problem that the invention aims to solve

[0010] The present invention aims to provide a class of tricyclic compounds with novel structures used as SOS1 inhibitors, which exhibit good inhibitory activity on tumor cells and good drugability and have broad prospects for drug development.

[0011] Solutions for solving problems

[0012] In a first aspect, the present invention provides a compound as shown in Formula I or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, metabolite or prodrug thereof:

[0013]

[0014] in,

[0015] A is selected from C6-C 10 aryl, 5- to 6-membered monocyclic heteroaryl, or 9- to 10-membered bicyclic heteroaryl;

[0016] L1 is selected from a single bond or a 5- to 6-membered monocyclic heteroaryl;

[0017] L2 is selected from a single bond, -O-, -S-, -NH-, -C(=O)-, -C(=O)O-, -S(=O)-, -S(=O)2-, -(CH2) m -, -C(=O)NH- or -C(=O)NR6-, wherein R6 is C1-C6 alkyl, and m is selected from 0, 1, 2 or 3;

[0018] X1, X2 and X3 are each independently selected from N or CR4;

[0019] X4, X5 are each independently selected from C or N;

[0020] Y1 and Y2 are each independently selected from N or CR4;

[0021] R1 is selected from hydrogen, deuterium, halogen, cyano, hydroxyl, amino, C1-C6 alkyl, C2-C8 heteroalkyl, C3-C8 cycloalkyl, C3-C8 heterocycloalkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy or C1-C6 haloalkyl, each of which is optionally substituted with at least 1 R5;

[0022] R2 is selected from hydrogen, deuterium, C1-C6 alkyl, C3-C8 cycloalkyl or C1-C6 haloalkyl, each of which is optionally substituted with at least one R5;

[0023] R3 is selected from C6-C 10 aryl, 5- to 6-membered monocyclic heteroaryl, 9- to 10-membered bicyclic heteroaryl, C1-C6 alkyl, C2-C8 heteroalkyl, C3-C8 cycloalkyl, or C3-C8 heterocycloalkyl, each of which is optionally substituted with at least 1 R5;

[0024] R4 is selected from hydrogen, deuterium, halogen, cyano, hydroxyl, amino, C1-C6 alkyl, C2-C8 heteroalkyl, C3-C8 cycloalkyl, C3-C8 heterocycloalkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 alkoxy or C1-C6 haloalkyl, each of which is optionally substituted with at least 1 R5;

[0025] R5 is selected from hydrogen, halogen, cyano, hydroxyl, amino, -N(R7)(R8), -C(=O)-N(R7)(R8), -C(=O)-R7, -C(=O)-OR7, C1-C6 alkyl, C3-C6 cycloalkyl, 3 to 8 membered heterocycloalkyl, C1-C3 alkoxy or C1-C6 haloalkyl, each of which is optionally substituted with at least one R7;

[0026] R7 and R8 are each independently selected from hydrogen, chloro, fluoro, cyano, hydroxy, amino, isopropyl, cyclopropyl, methyl, difluoromethyl, trifluoromethyl, methoxy, trifluoromethoxy, ethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy or phenyl.

[0027] Preferably, it is a compound as shown in any one of formula (II), (III) and (IV),

[0028]

[0029] More preferably, it is a compound as shown in any one of formula (V), (VI) or (VII),

[0030]

[0031] More preferably, it is a compound represented by any one of formula (V-1), (V-2), (V-3), (VI-1), (VI-2), (VI-3), (VII-1), (VII-2), or (VII-3),

[0032]

[0033]

[0034] In a second aspect, the present invention provides a specific compound as shown in Formula I, (II), (III), (IV), (V), (VI), (VII), (V-1), (VI-2) or (VII-3), which is a compound as shown in Formula 1 or 2:

[0035]

[0036] Those skilled in the art can select the groups and substituents thereof in the general formula of the above-mentioned compounds to provide stable compounds, or pharmaceutically acceptable salts thereof, or stereoisomers thereof, or tautomers thereof, or hydrates thereof, or solvates thereof, or metabolites thereof, or prodrugs thereof, including but not limited to the compounds described in the embodiments of the present invention.

[0037] In a third aspect, the present invention provides a pharmaceutical composition comprising an effective dose of a compound as described in any one of Formulas I, (II), (III), (IV), (V), (VI), (VII), (V-1), (VI-2), and (VII-3), or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a tautomer thereof, or a hydrate thereof, or a solvate thereof, or a metabolite thereof, or a prodrug thereof, and at least one pharmaceutically acceptable excipient.

[0038] In a fourth aspect, the above-mentioned compound provided by the present invention, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a tautomer thereof, or a hydrate thereof, or a solvate thereof, or a metabolite thereof, or a prodrug thereof, or a pharmaceutical composition thereof can be used to prepare an SOS1 inhibitor for treating a disease caused by overexpression of SOS1.

[0039] In a fifth aspect, in some embodiments of the present invention, the above-mentioned compounds, or pharmaceutically acceptable salts thereof, or stereoisomers thereof, or tautomers thereof, or hydrates thereof, or solvates thereof, or metabolites thereof, or prodrugs thereof, or pharmaceutical compositions thereof provided by the present invention are used in the preparation of drugs for treating and / or preventing cancer. The compounds described in the present invention can be used to treat and / or prevent cancer, wherein the cancers that can be used to treat and / or prevent include but are not limited to pancreatic cancer, colorectal cancer, and lung cancer.

[0040] Effects of the Invention

[0041] The present invention provides a series of novel tricyclic compounds. The relevant enzyme and cell activity tests prove that the compounds of the present invention have excellent cell proliferation inhibition activity. In in vitro experiments, the IC 50 The value reaches nM level, and can be well applied in various tumors. At the same time, the compounds of the present invention have a very good inhibitory effect on KRAS:SOS1 activation, which can reach nM level, and are suitable for preparation into SOS1 inhibitors for preventing and / or treating diseases or conditions related to SOS1 activation, such as cancer (including but not limited to pancreatic cancer, colorectal cancer and lung cancer). DETAILED DESCRIPTION

[0042] General Terms and Definitions

[0043] Unless otherwise stated, the terms used in the present invention have the following meanings.

[0044] "Alkyl" refers to a saturated aliphatic hydrocarbon group, including straight and branched groups of 1 to 20 carbon atoms, for example, straight and branched groups of 1 to 18 carbon atoms, 1 to 12 carbon atoms, 1 to 8 carbon atoms, 1 to 6 carbon atoms or 1 to 4 carbon atoms. In the present invention, "alkyl" can be a monovalent, divalent or trivalent group. Non-limiting examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl and various branched chain isomers thereof, etc. Non-limiting examples also include, but are not limited to, methylene, methine, ethylene, ethylene, propylene, propylene, butylene, butylene and various branched chain isomers thereof. In addition, in the present invention, "alkyl" may be optionally substituted or unsubstituted.

[0045] "Alkoxy" refers to an "-O-alkyl" group wherein "alkyl" is as defined above.

[0046] "Alkenyl" refers to an unsaturated aliphatic hydrocarbon group, including straight and branched groups of 1 to 20 carbon atoms and at least 1 carbon-carbon double bond, for example, straight and branched groups of 1 to 18 carbon atoms, 1 to 12 carbon atoms, 1 to 8 carbon atoms, 1 to 6 carbon atoms or 1 to 4 carbon atoms. In the present invention, "alkenyl" can be a monovalent, divalent or trivalent group. Non-limiting examples include, but are not limited to, vinyl (-CH=CH2), propene-1-yl (-CH=CH-CH3), propene-2-yl (-C(CH3)=CH2), butene-1-yl (-CH=CH-CH2-CH3), butene-2-yl (-C(C2H5)=CH2), 1-methylpropene-1-yl (-C(CH3)=CH-CH3) and various branched isomers thereof, etc. Non-limiting examples also include, but are not limited to, 1,1-vinylene (=C=CH2), 1,2-vinylene (-CH=CH-), 1,1-propenylene (=C=CH-CH3), 1,2-propenylene (-CH=C(CH3)-), 1,3-propenylene (-CH=CH-CH2-) and various branched isomers thereof. In addition, in the present invention, "alkenyl" may be optionally substituted or unsubstituted.

[0047] "Alkynyl" refers to an unsaturated aliphatic hydrocarbon group, including straight and branched chain groups of 1 to 20 carbon atoms and at least one carbon-carbon triple bond, for example, straight and branched chain groups of 1 to 18 carbon atoms, 1 to 12 carbon atoms, 1 to 8 carbon atoms, 1 to 6 carbon atoms, or 1 to 4 carbon atoms. In the present invention, "alkynyl" can be a monovalent, divalent, or trivalent group. Non-limiting examples include, but are not limited to, ethynyl. Propynyl Butynyl Pentynyl and its various branched chain isomers, etc. Non-limiting examples also include, but are not limited to, ethynyl Propylene Butynylene and various branched isomers thereof. In addition, in the present invention, "alkynyl" may be optionally substituted or unsubstituted.

[0048] "Heteroalkyl" refers to a saturated aliphatic hydrocarbon group, including straight and branched chain groups of 2 to 20 atoms, for example, straight and branched chain groups of 2 to 18 atoms, 2 to 12 atoms, 2 to 8 atoms, 2 to 6 atoms or 2 to 4 atoms, wherein one or more atoms is selected from nitrogen, oxygen or S(O) m (wherein m is 0, 1 or 2) heteroatoms, and the rest are carbon. In the present invention, "heteroalkyl" can be a monovalent, divalent or trivalent group. Non-limiting examples include, but are not limited to, methoxymethyl (2-oxapropyl), methylthiomethyl (2-thiapropyl), methylaminomethyl (2-aziridine propyl) and various branched chain isomers thereof. In addition, in the present invention, "heteroalkyl" can be optionally substituted or unsubstituted.

[0049] "Cycloalkyl" refers to a saturated or partially unsaturated, monocyclic or polycyclic aliphatic hydrocarbon group, including 3 to 12 ring atoms, for example, 3 to 12, 3 to 10 or 3 to 6 ring atoms (i.e., 3 to 6 rings). Non-limiting examples of monocyclic cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, etc. In the present invention, "cycloalkyl" can be optionally substituted or unsubstituted.

[0050] "Heterocycloalkyl" refers to a saturated or partially unsaturated, monocyclic or polycyclic aliphatic hydrocarbon group comprising 3 to 20 ring atoms, for example 3 to 16, 3 to 12, 3 to 10 or 3 to 6 ring atoms, wherein one or more of the ring atoms is selected from nitrogen, oxygen or S(O) m(wherein m is 0,1 or 2) heteroatoms, and all the other ring atoms are carbon.Preferably heterocycloalkyl includes 3 to 12 ring atoms, wherein 1 to 4 ring atoms are heteroatoms, more preferably includes 3 to 10 ring atoms, most preferably includes 5 or 6 ring atoms, wherein 1 to 4, preferably 1 to 3, more preferably 1 to 2 are heteroatoms.The limiting examples of monocyclic heterocycloalkyl include but are not limited to pyrrolidinyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl etc.The limiting examples of polycyclic heterocycloalkyl include but are not limited to the heterocycloalkyl of spirocycle or bridged ring.

[0051] "Halogen" refers to fluorine, chlorine, bromine and iodine, with fluorine, chlorine and bromine being preferred.

[0052] "Haloalkyl" or "haloalkoxy" refers to an alkyl or alkoxy group substituted by one or more halogen atoms which are the same or different. Preferred examples of alkyl or alkoxy include, but are not limited to, trifluoromethyl, trifluoroethyl, and trifluoromethoxy.

[0053] "Cyano" refers to a "-CN" group.

[0054] "Hydroxy" refers to a "-OH" group.

[0055] "Amino" refers to a "-NH2" group.

[0056] "Carbamoyl" refers to a "-(C=O)-NH2" group.

[0057] "Aryl" refers to monocyclic, bicyclic and tricyclic carbon ring systems containing 6-14 ring atoms, wherein at least one ring system is aromatic, wherein each ring system contains a ring consisting of 3-7 atoms and has one or more points of attachment to the rest of the molecule. Examples include, but are not limited to, phenyl, naphthyl, anthracene, etc. Preferably, the aryl group is a carbon ring system of 6-10 or 6-7 ring atoms.

[0058] "Heteroaryl" refers to monocyclic, bicyclic and tricyclic ring systems containing 5-14 ring atoms, wherein at least one ring system is aromatic and at least one ring system contains one or more heteroatoms selected from nitrogen, oxygen and sulfur, wherein each ring system contains a ring consisting of 5-7 atoms and has one or more points of attachment to the rest of the molecule. The term "heteroaryl" can be used interchangeably with the terms "heteroaromatic ring" or "heteroaromatic compound". Examples include, but are not limited to: furanyl, imidazolyl, 2-pyridyl, 3-pyridyl, thiazolyl, purinyl, quinolyl. Preferably, the heteroaryl is a ring system of 5-10 ring atoms.

[0059] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs or does not occur. For example, "a heterocyclic group optionally substituted with an alkyl group" means that the alkyl group may but need not be present, and the description includes instances where the heterocyclic group is substituted with an alkyl group and instances where the heterocyclic group is not substituted with an alkyl group.

[0060] "Substituted" means that one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms in the group are replaced independently of one another by a corresponding number of substituents.

[0061] "Pharmaceutically acceptable salt" refers to a salt prepared from a compound of the present invention and a relatively non-toxic acid or base. When the compound of the present invention contains a relatively acidic functional group (e.g., a carboxyl group or a sulfonic acid group), a base addition salt can be obtained by contacting its free form with a sufficient amount of a base in a pure solution or a suitable inert solvent. Non-limiting examples of pharmaceutically acceptable base addition salts include, but are not limited to, sodium salts, potassium salts, ammonium salts, calcium salts, magnesium salts, organic amine salts, or similar salts. When the compound of the present invention contains a relatively alkaline functional group (e.g., an amino group or a guanidine group), an acid addition salt can be obtained by contacting its free form with a sufficient amount of an acid in a pure solution or a suitable inert solvent. Non-limiting examples of pharmaceutically acceptable acid addition salts include, but are not limited to, inorganic acid salts (e.g., hydrochlorides, hydrobromides, hydroiodides, nitrates, carbonates, bicarbonates, phosphates, monohydrogen phosphates, dihydrogen phosphates, phosphites, sulfates, hydrogen sulfates, etc.), organic acid salts (e.g., acetates, propionates, isobutyrates, malonates, succinates, suberates, maleates, fumarates, citrates, tartrates, lactates, mandelates, benzoates, phthalates, methanesulfonates, benzenesulfonates, p-toluenesulfonates, glucuronic acid, etc.), and amino acid salts (e.g., arginine salts, etc.). Specific forms of pharmaceutically acceptable salts can also be found in Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science, 1977, 66: 1-19). Certain specific compounds of the present invention contain basic and acidic functional groups and can be converted into either base addition salts or acid addition salts. Preferably, the salt is contacted with an alkali or acid in a conventional manner, and the parent compound is separated, thereby regenerating the neutral form of the compound. The parent form of the compound differs from its various salt forms in certain physical properties, such as different solubility in polar solvents. According to embodiments of the present invention, the pharmaceutically acceptable salt of the compound preferably as shown in Formula I is an acid addition salt, preferably hydrochloride, hydrobromide, phosphate or sulfate, more preferably hydrochloride.

[0062] A "pharmaceutical composition" refers to a composition for pharmaceutical use, which comprises one or more compounds as shown in Formula I or a pharmaceutically acceptable form thereof (e.g., salts, hydrates, solvates, stereoisomers, tautomers, metabolites, prodrugs, etc.), and other components (e.g., pharmaceutically acceptable excipients).

[0063] In the present invention, "pharmaceutically acceptable excipients" refer to auxiliary materials widely used in the field of drug production. The main purpose of using excipients is to provide a pharmaceutical composition that is safe to use, stable in nature and / or has specific functionality, and also to provide a method so that after the drug is administered to the subject, the active ingredient can be dissolved at a desired rate, or to promote the effective absorption of the active ingredient in the subject receiving the drug. Pharmaceutically acceptable excipients can be inert fillers, or they can be functional ingredients that provide a certain function for the pharmaceutical composition (for example, stabilizing the overall pH value of the composition or preventing the degradation of the active ingredient in the composition). Non-limiting examples of pharmaceutically acceptable excipients include, but are not limited to, adhesives, suspending agents, emulsifiers, diluents (or fillers), granulating agents, adhesives, disintegrants, lubricants, anti-adhesive agents, glidants, wetting agents, gelling agents, absorption delay agents, dissolution inhibitors, enhancers, adsorbents, buffers, chelating agents, preservatives, colorants, flavoring agents, sweeteners, etc.

[0064] The pharmaceutical compositions of the present invention can be prepared by any method known to those skilled in the art, for example, conventional mixing, dissolving, granulating, emulsifying, grinding, encapsulating, embedding and / or lyophilizing processes.

[0065] In the present invention, the purpose of using the pharmaceutical composition is to promote the administration of the organism, which is conducive to the absorption of the active ingredient and then exerts biological activity. The pharmaceutical composition of the present invention can be administered in any form, including injection (intra-arterial, intravenous, intramuscular, intraperitoneal, subcutaneous), mucosal, oral (oral solid preparations, oral liquid preparations), rectal, inhalation, implantation, local (e.g., eye) administration, etc. Non-limiting examples of oral solid preparations include, but are not limited to, powders, capsules, lozenges, granules, tablets, etc. Non-limiting examples of liquid preparations for oral or mucosal administration include, but are not limited to, suspensions, tinctures, elixirs, solutions, etc. Non-limiting examples of topical preparations include, but are not limited to, emulsions, gels, ointments, creams, patches, pastes, foams, lotions, drops or serum preparations. Non-limiting examples of parenteral preparations include, but are not limited to, solutions for injection, dry powders for injection, suspensions for injection, emulsions for injection, etc. The pharmaceutical composition of the present invention can also be made into controlled release or delayed release dosage forms (e.g., liposomes or microspheres).

[0066] Preferably, the compound of the present invention or the pharmaceutical composition comprising the same is administered orally or intravenously to an individual in need thereof. Depending on the specific circumstances of the subject to be administered, other routes of administration may also be applicable or even preferred. For example, for patients who are forgetful or irritable to oral medications, transdermal administration will be a very important route of administration. In the present invention, the route of administration can be changed or adjusted in any suitable manner to meet the needs of the nature of the drug, the convenience of the patient and medical staff, and other relevant factors.

[0067] The compound of the present invention or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, metabolite or prodrug or pharmaceutical composition comprising the same has excellent SOS1 enzyme activity and cell proliferation inhibitory activity, can be used as an SOS1 inhibitor for preventing and / or treating diseases or conditions caused by overexpression of SOS1, and has good clinical application and medical use. Preferably, a non-limiting example of a disease or condition caused by overexpression of SOS1 is cancer, including but not limited to pancreatic cancer, colorectal cancer and lung cancer.

[0068] The technical scheme of the present invention will be described below in conjunction with specific embodiments. The following embodiments are provided to further illustrate the present invention, but are not intended to limit the scope of the present invention. It will be apparent to those skilled in the art that various changes and improvements can be made to the specific embodiments of the present invention without departing from the spirit and scope of the present invention.

[0069] The preparation of the compounds of the present invention can be achieved by synthetic methods well known to those skilled in the art, including but not limited to the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent substitution methods well known to those skilled in the art, and preferred embodiments include but are not limited to the embodiments of the present invention. The known starting materials used in the present invention can be synthesized by methods known in the art, or purchased by conventional commercial means (for example, purchased from Shaoyuan Chemical Technology, Beijing Coupling Technology, etc.). Unless otherwise specified, the reactions are carried out under an argon atmosphere or a nitrogen atmosphere. The hydrogenation reaction is usually evacuated, filled with hydrogen, and the operation is repeated 3 times. The reaction temperature is room temperature, and the temperature range is 20°C-30°C. Monitoring of the reaction progress can be achieved by synthetic methods well known to those skilled in the art, including but not limited to thin layer chromatography (TLC). The thin layer chromatography silica gel plate uses Qingdao Ocean GF254 silica gel plate, and the developing solvent system includes but is not limited to A: dichloromethane and methanol system; B: petroleum ether and ethyl acetate system, and the volume ratio of the solvent can be adjusted according to the polarity of the compound.

[0070] The separation and purification of the compounds of the present invention can be achieved by synthetic methods well known to those skilled in the art, including but not limited to column chromatography (CC), high performance liquid chromatography (HPLC), ultra-high performance liquid chromatography (UPLC), etc. Column chromatography generally uses Qingdao Ocean 200-300 mesh silica gel as a carrier, and the eluent system includes but is not limited to A: dichloromethane and methanol system; B: petroleum ether and ethyl acetate system. The volume ratio of the solvent can be adjusted according to the polarity of the compound, and a small amount of acidic or alkaline anti-tailing reagent can also be added for adjustment. The HPLC spectrum is measured using an Agilent 1200DAD HPLC chromatograph (chromatographic column: Sunfire C18, 150×4.6 mm, 5 μm) or a Waters 2695-2996 HPLC chromatograph (chromatographic column: Gimini C18, 150×4.6 mm, 5 μm).

[0071] The structural identification of the compounds of the present invention can be achieved by methods well known to those skilled in the art, including but not limited to nuclear magnetic resonance (NMR), mass spectrometry (MS), etc. The NMR spectrum was measured using a Bruker AVANCE-400 or Varian Oxford-300 nuclear magnetic spectrometer, the measurement solvent was deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDC13) or deuterated methanol (CD3OD), the internal standard was tetramethylsilane (TMS), and the chemical shift was 10 -6 The MS spectra were measured using an Agilent SQD (ESI) mass spectrometer (model: 6110) or a Shimadzu SQD (ESI) mass spectrometer (model: 2020).

[0072] The present invention is described in detail below by examples, but it is not intended to limit the present invention in any adverse way. The compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by combining them with other chemical synthesis methods, and equivalent substitutions well known to those skilled in the art, and preferred embodiments include but are not limited to the embodiments of the present invention. It will be apparent to those skilled in the art that various changes and improvements can be made to the specific embodiments of the present invention without departing from the spirit and scope of the present invention. The following synthetic schemes describe the steps for preparing the compounds disclosed in the present invention. Unless otherwise indicated, each substituent has a definition as described in the present invention.

[0073] Option A:

[0074]

[0075] Compound A1 and orthoformic acid or orthoacetic acid ester compounds undergo high temperature ring closure to obtain A2, which is then reacted with phosphorus oxychloride to obtain A3. Compound A3 reacts with the corresponding chiral amine compound under alkaline conditions to obtain A4. Compound A4 reacts with ammonia methanol, or reacts with p-methoxybenzylamine and then deprotects to finally obtain A5. Compound A5 undergoes a ring closure reaction with a suitable ring closure reagent, such as chloroacetaldehyde, bromoacetaldehyde diethyl acetal, to obtain A6. Compound A6 undergoes a coupling reaction with other compounds, such as amines, boric acids, and boron ester compounds to obtain a derivative of compound formula (V-1).

[0076] Preparation and functional verification of target compounds

[0077] Example 1: Preparation of Compound 1

[0078]

[0079] The synthetic route of compound 1 is:

[0080]

[0081] The specific preparation method of compound 1 includes:

[0082] Step 1: Synthesis of Compound B

[0083] Compound A (1.0 g, 4.02 mmol, 1.0 eq) was dissolved in triethyl orthoacetate (20 ml, 20 V), and ammonium formate (1.27 g, 20.1 mmol, 5.0 eq) was added to the reaction solution, and then the reaction solution was placed in a jar, heated to 140° C., stirred and reacted overnight. After TLC showed that the reaction was completed, the reaction solution was cooled to room temperature, and 20 mL of water was added to the reaction solution, and a large amount of khaki solid was produced. The solid was filtered and the filter cake was dried to obtain compound B (0.5 g, khaki solid, yield 45.4%).

[0084] MS (ESI): m / z 274 [M+1] + .

[0085] Step 2: Synthesis of Compound C

[0086] Compound B (0.5 g, 1.83 mmol, 1.0 eq) was dissolved in MeCN (10 mL, 20 V), DIEA (0.94 g, 7.32 mmol, 4.0 eq) was added to the reaction solution, and then POCl3 (1.12 g, 7.32 mmol, 4.0 eq) was added dropwise at 30 ° C. After the addition was complete, the reaction solution was heated to 80 ° C and stirred for 2 h. After TLC showed that the reaction was completed, acetonitrile was removed by spin drying, ethyl acetate (10 mL) and saturated NaHCO3 solution (10 mL) were added to the reaction solution, the organic phase was separated, the aqueous phase was extracted twice with ethyl acetate (5 mL * 2), the organic phases were combined, dried, spin dried, and the residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5: 1) to obtain compound C (0.4 g, light yellow solid, yield 75.5%).

[0087] MS (ESI): m / z 292 [M+1] + .

[0088] Step 3: Synthesis of Compound E

[0089] Compound C (0.4 g, 1.37 mmol, 1.0 eq) was dissolved in DMF (4 mL, 10 V), and compound D (0.26 g, 1.37 mmol, 1.0 eq) and DIEA (0.35 g, 2.74 mmol, 2.0 eq) were added to the reaction solution. After the addition, the reaction solution was heated to 70 ° C and stirred for 16 h. After TLC showed that the reaction was completed, ethyl acetate (10 mL) and saturated NaCl solution (10 mL) were added to the reaction solution, and the organic phase was separated. The aqueous phase was extracted twice with ethyl acetate (5 mL * 2), and the organic phases were combined, dried, and spin-dried. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 3:1) to obtain compound E (0.4 g, yellow solid, yield 61.2%).

[0090] MS (ESI): m / z 445 [M+1] + .

[0091] Step 4: Synthesis of Compound F

[0092] Compound E (0.4 g, 0.9 mmol, 1.0 eq) was dissolved in MeCN (4 mL, 10 V), and then compound PMBNH2 (0.14 g, 0.99 mmol, 1.1 eq) and DIEA (0.23 g, 2.74 mmol, 2.0 eq) were added to the reaction solution. After the addition, the reaction solution was heated to 80 ° C and stirred for 5 h. After TLC showed that the reaction was completed, the product was dried by spin drying, and the residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1:1) to obtain compound F (0.4 g, yellow solid, yield 81.6%).

[0093] MS (ESI): m / z 546 [M+1] + .

[0094] Step 5: Synthesis of Compound G

[0095] At 0°C, compound F (0.4 g, 0.73 mmol, 1.0 eq) was added to CF3COOH (8 mL, 20 V) in batches. After the addition was complete, the reaction solution was heated to 25°C and stirred for 1 h. After TLC showed that the reaction was complete, ethyl acetate (20 mL) was added to the reaction solution, and then a saturated sodium carbonate solution (20 mL) was added dropwise until pH = 8, the organic phase was separated, and the aqueous phase was extracted twice with ethyl acetate (5 mL*2), the organic phases were combined, dried, and spin-dried, and the residue was purified by silica gel column chromatography (eluent: ethyl acetate) to obtain compound G (0.3 g, light yellow solid, yield 96.8%).

[0096] MS (ESI): m / z 426 [M+1] + .

[0097] Step 6: Synthesis of Compound H

[0098] Compound G (0.3 g, 0.7 mmol, 1.0 eq) was dissolved in ethanol / water (4 mL / 2 mL, 20 V), and then 48% HBr (0.3 mL) solution was added dropwise, and then bromoacetaldehyde diethyl acetal (0.69 g, 3.5 mmol, 5.0 eq) was added, and then the reaction solution was heated to 110° C. and refluxed for 8 h. After TLC showed that the reaction was completed, ethyl acetate (20 mL) was added to the reaction solution, and then saturated sodium bicarbonate solution (10 mL) was added dropwise until pH = 8, and the organic phase was separated, and the aqueous phase was extracted twice with ethyl acetate (5 mL*2), and the organic phases were combined, dried, and spin-dried. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 3:1) to obtain compound H (0.15 g, brown-yellow solid, yield 46.9%).

[0099] MS (ESI): m / z 450 [M+1] + .

[0100] 1H NMR(300MHz,dmso)δ8.65(d,J=7.1Hz,1H),8.58(s,1H),8.38(d,J=1.4Hz,1H),7.69(t,J=7.5Hz,1H),7.64(d,J=1.4Hz, 1H),7.50(t,J=7.0Hz,1H),7.29(t,J=7.7Hz,1H),7.23(t,J=57Hz,1H),5.77(m,1H),2.42(s,3H),1.59(d,J=7.1Hz,3H).

[0101] Step 7: Synthesis of Compound J

[0102] Compound H (30 mg, 0.067 mmol, 1.0 eq) and compound I (25 mg, 0.074 mmol, 1.1 eq) were dissolved in dioxane / water (1.5 mL / 0.3 mL, 40 V), and cesium carbonate (32.6 mg, 0.067 mmol, 1.5 eq) and Pd(dppf)Cl2.DCM (3 mg, 0.0037 mmol, 0.05 eq) were added to the reaction solution, and nitrogen was replaced three times, and then the reaction solution was heated to 100 ° C. and reacted for 3 hours under nitrogen protection. After TLC showed that the reaction was completed, the reaction solution was prepared and separated and purified by TLC plate (eluent: petroleum ether / ethyl acetate = 3:1) to obtain compound J (25 mg, off-white solid, yield 64.1%).

[0103] MS (ESI): m / z 587 [M+1] + .

[0104] Step 8: Synthesis of Compound K

[0105] Compound J (25 mg, 0.043 mmol, 1.0 eq) was dissolved in glacial acetic acid (1 mL, 40 V), and 10% wet Pd / C (25 mg) was added to the reaction solution, and hydrogen was replaced three times. Then, the reaction solution was heated to 50° C. and the hydrogen pressure was maintained at 30 psi and stirred for 1 h. After TLC showed that the reaction was complete, the reaction solution was concentrated to dryness to obtain a crude compound K (20 mg, green oil, yield 100%).

[0106] MS (ESI): m / z 467 [M+1] + .

[0107] Step 9: Synthesis of Compound 1

[0108] Compound K (20 mg, 0.043 mmol, 1.0 eq) was dissolved in DCM (1 mL, 50 V), and Ac2O (4.4 mg, 0.043 mmol, 1.0 eq) and TEA (8.7 mg, 0.086 mmol, 2.0 eq) were added to the reaction solution, and then the reaction solution was stirred at 25° C. for 1 h. After TLC showed that the reaction was complete, the reaction solution was concentrated to dryness and separated by HPLC to obtain compound 1 (1.7 mg, white solid, yield 8.1%).

[0109] MS (ESI): m / z 497 [M+1] + .

[0110] 1 H NMR (300MHz, DMSO-d6) δ8.50(d,J=7.1Hz,1H),8.25(d,J=1.3Hz,1H),7.90(s,1H),7.67(t, J=7.1Hz,1H),7.57(d,J=1.3Hz,1H),7.50(t,J=6.9Hz,1H),7.30(t,J=7.7Hz,1H),7.23((t ,J=54Hz,1H),5.80(m,1H),4.63(d,J=12.5Hz,1H),3.99(d,J=14.2Hz,1H),3.21(m,2H),2. 67(m,1H),2.41(s,3H),2.05(s,3H),1.96(m,2H),1.85–1.67(m,2H),1.61(d,J=7.0Hz,3H).

[0111] Example 2: Preparation of Compound 2

[0112]

[0113] The synthesis of compound 2 refers to the synthesis steps of compound 1 in Example 1, wherein triethyl orthoacetate is used in the first step instead of trimethyl orthoacetate to synthesize compound 2.

[0114] MS (ESI): m / z 483 [M+1] + .

[0115] 1H-NMR(300MHz,DMSO-d6)δ8.61(d,J=5.9Hz,1H),8.45(s,1H),8.32(s,1H),7.97 (s,1H),7.62(m,2H),7.51(t,J=6.0Hz,1H),7.30(t,J=6.0Hz,1H),7.23(t,J=51H z,1H),5.80(m,1H),4.64(d,J=11.1Hz,1H),4.01(d,J=12.1Hz,1H),3.25(m,2H), 2.68(m,1H),2.06(s,3H),2.03–1.92(m,2H),1.78(m,2H),1.62(d,J=6.2Hz,3H).

[0116] Experimental Example 1: KRAS (G12C) and SOS1 binding experiment

[0117] This assay can be used to examine the potency of compounds to inhibit the protein-protein interaction between SOS1 and KRAS G12C. 50 The values ​​indicate high potency of the compounds as SOS1 inhibitors in the following assay setup.

[0118] 1. Experimental materials:

[0119] KRAS (G12C) protein was synthesized by Pujian Biotechnology Co., Ltd.;

[0120] SOS1 protein exchange human recombinant domain protein (564-1049) was purchased from Cytoskeleton;

[0121] Mab Anti 6HIS-XL665 and Mab Anti GST-Eu cryptate were purchased from Cisbio.

[0122] 2. Experimental methods:

[0123] 1X buffer preparation (prepared and used immediately): Hepes: 5 mM; NaCl: 150 mM; EDTA: 10 mM; Igepal: 0.0025%; KF: 100 mM; DTT: 1 mM; BSA: 0.05%.

[0124] The compound to be tested was diluted 3-fold to the eighth concentration, ie, from 100 μM to 45.7 nM, using a dispenser.

[0125] The compounds to be tested were diluted with 1X buffer to a working solution with 2% DMSO, and 5 μL / well was added to the corresponding wells to set up a double-well experiment. Centrifuged at 1000 rpm for 1 min.

[0126] A mixed working solution of KRAS (G12C) (200 nM) and Mab Anti GST-Eu cryptate (1 ng / μL) was prepared with 1X buffer, incubated at 25°C for 5 min, and 2.5 μL / well was added to the corresponding wells.

[0127] A mixed working solution of SOS1 (80nM) and Mab Anti 6HIS-XL665 (8g / μL) was prepared with 1X buffer, and 2.5μL / well was added to the corresponding wells. 2.5μL of Mab Anti 6HIS-XL665 (8g / μL) dilution was added to the Blank wells. At this time, the final concentration gradient of the compound was diluted from 1μM to 0.457nM, KRAS (G12C) (500nM), MAb Anti GST-Eu cryptate (0.25ng / μL), SOS1 (20nM), Mab Anti 6HIS-XL665 (2g / μL), and the reaction system was placed at 25°C for 60min. After the reaction, HTRF was read using a multi-label analyzer.

[0128] Max well: 1% DMSO, KRAS (G12C) (500nM), MAb Anti GST-Eu cryptate (0.25ng / μL), SOS1 (20nM), Mab Anti 6HIS-XL665 (2g / μL)

[0129] Min well: 1% DMSO, KRAS (G12C) (500nM), MAb Anti GST-Eu cryptate (0.25ng / μL), Mab Anti 6HIS-XL665 (2g / μL)

[0130] 3. Data Analysis:

[0131] The raw data were converted into inhibition rate, IC using the equation (sample-Min) / (Max-Min)×100%. 50 The value can be obtained by four-parameter curve fitting (obtained by log(inhibitor) vs.response--Variable slope mode in GraphPad Prism).

[0132] The inhibitory activity of the compounds prepared by the present invention on the binding of KRAS (G12C) to SOS1 is shown in Table 1, wherein + represents >1uM, ++ represents 100nM-1uM, +++ represents 10nM-100nM, ++++ represents <10nM, and ND represents not tested.

[0133] Table 1. IC of the compounds of the present invention for inhibition of binding between KRAS (G12C) and SOS1 50 data

[0134] Compound No. <![CDATA[IC 50 (nM)]]> Compound 1 +++ Compound 2 +++

[0135] As can be seen from Table 1, the compounds of the present invention have a good inhibitory effect on SOS1 and have a significant inhibitory effect on the combination of KRAS (G12C) and SOS1. The inhibitory effect of the compounds is less than 100 nM, and has a good prospect for clinical application.

[0136] Experimental Example 2: p-ERK Experiment

[0137] 1. Experimental materials:

[0138] DLD-1 cells were purchased from Wuhan Pronocell Life Science Co., Ltd.; 1640 culture medium was purchased from Biological Industries; fetal bovine serum was purchased from Biosera; Advanced Phospho-ERK1 / 2 (THR202 / TYR204) KIT was purchased from Cisbio.

[0139] 2. Experimental methods:

[0140] DLD-1 cells were seeded in a transparent 96-well cell culture plate, with 80 μL of cell suspension per well, and each well contained 8,000 DLD-1 cells. The cell plate was placed in a carbon dioxide incubator and incubated at 37 degrees overnight;

[0141] The compound to be tested was diluted to 2 mM with 100% DMSO as the first concentration, and then diluted 5 times with a pipette to the eighth concentration, that is, from 2 mM to 0.026 μM. 2 μL of compound was added to 78 μL of cell starvation medium, mixed, and 20 μL of compound solution was added to the corresponding cell plate wells. The cell plate was returned to the carbon dioxide incubator and incubated for 1 hour. At this time, the compound concentration was 10 μM to 0.128 nM, and the DMSO concentration was 0.5%;

[0142] After the incubation, discard the cell supernatant and add 50 μL of cell lysis buffer to each well, and incubate at room temperature with shaking for 30 minutes;

[0143] Use detection buffer to dilute Phospho-ERK1 / 2Eu Cryptate antibody and Phospho-ERK1 / 2d2antibody 20 times;

[0144] Take 16 μL of cell lysate supernatant per well into a new 384-well white microplate, add 2 μL of Phospho-ERK1 / 2Eu Cryptate antibody dilution and 2 μL of Phospho-ERK1 / 2d2 antibody dilution, and incubate at room temperature for 4 hours;

[0145] After incubation, use a multi-label analyzer to read HTRF excitation: 320nm, emission: 615nm, 665nm.

[0146] 3. Data Analysis:

[0147] The raw data were converted into inhibition rate, IC using the equation (Sample-Min) / (Max-Min)*100%. 50 The value can be obtained by curve fitting with four parameters (obtained by log(inhibitor) vs.response--Variable slope mode in GraphPad Prism). The inhibitory activity of the compounds prepared by the present invention on DLD-1 cell phosphorylation is shown in Table 2, where + represents >1uM, ++ represents 100nM-1uM, +++ represents 10nM-100nM, ++++ represents <10nM, and ND represents not tested.

[0148] Table 2. Test results of the phosphorylation inhibition activity of the compounds of the present invention on DLD-1 cells IC 50 data

[0149] Compound No. <![CDATA[IC 50 (nM)]]> Compound 1 ++ Compound 2 +++

[0150] As can be seen from Table 2, the compounds of the present invention have a good inhibitory effect on the phosphorylation of DLD-1 cells and have a good clinical application prospect.

[0151] Although the embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and cannot be understood as limiting the present invention. Without departing from the principles and purpose of the present invention, those skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention, and these changes, modifications, replacements and modifications are all included in the scope of the present invention.

Claims

1. A compound as shown in Formula 1 or 2, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof: 。 2. A pharmaceutical composition, characterized in that The composition comprises an effective dose of the compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and at least one pharmaceutically acceptable excipient.

3. Use of the compound according to claim 1 or its pharmaceutically acceptable salt or stereoisomer thereof or the pharmaceutical composition according to claim 2 in the preparation of a medicament for treating a disease caused by overexpression of SOS1.

4. Use of the compound according to claim 1 or its pharmaceutically acceptable salt or stereoisomer thereof or the pharmaceutical composition according to claim 2 in the preparation of a SOS1 inhibitor drug.

5. Use of the compound according to claim 1 or its pharmaceutically acceptable salt or stereoisomer thereof or the pharmaceutical composition according to claim 2 in the preparation of a drug for treating and / or preventing cancer.